Illumina Inc (ILMN.OQ)
72.00USD
17 May 2013
$2.35 (+3.37%)
$69.65
$70.13
$72.39
$69.66
446,708
353,090
$77.11
$37.77
ILMN.OQ
About
Overall
| Beta: | 0.66 |
| Market Cap (Mil.): | $8,955.25 |
| Shares Outstanding (Mil.): | 124.38 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ILMN.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 96.26 | 76.95 | 35.83 |
| EPS (TTM): | 0.75 | -- | -- |
| ROI: | 4.72 | 4.23 | 18.72 |
| ROE: | 8.29 | 9.06 | 19.54 |
BRIEF-Illumina shares up 4.3 pct after the bell
NEW YORK, April 22 - Illumina Inc : * Shares up 4.3 percent after the bell following results
CORRECTED-BRIEF-Illumina ordered to pay about $96 mln in patent damages
March 14 - March 14 - Illumina Inc :
BRIEF-Illumina shares down in premarket
NEW YORK, Jan 7 - Illumina Inc : * Down 7.3 percent to $50.75 in premarket
Swiss stocks - Factors to watch on Jan 7
ZURICH, Jan 7 - The following are some of the main factors expected to affect Swiss stocks on Monday.
Illumina to buy Verinata Health for $350 mln plus milestone payments
Jan 7 - U.S. genetic sequencing company Illumina Inc said it has agreed to buy Verinata Health Inc for $350 million plus up to $100 million in milestone payments through 2015 to expand its footprint in prenatal testing options.
Roche chairman says Illumina bid off the table: paper
ZURICH - Swiss pharmaceutical group Roche is no longer considering a bid for U.S. gene-sequencing company Illumina , Chairman Franz Humer was quoted as saying in a newspaper interview on Sunday.
Illumina shares jump on report of new Roche bid
ZURICH - Shares in Illumina jumped 7 percent on Thursday, after Swiss newspaper L'Agefi reported that Roche may have reached an agreement to buy the U.S. gene-sequencing company.
Illumina shares jump on report of new Roche bid
ZURICH - Shares in Illumina jumped 7 percent on Thursday, after Swiss newspaper L'Agefi reported that Roche may have reached an agreement to buy the U.S. gene-sequencing company.
Illumina shares jump on report of new Roche bid
ZURICH, Dec 20 - Shares in Illumina jumped 7 percent on Thursday, after Swiss newspaper L'Agefi reported that Roche may have reached an agreement to buy the U.S. gene-sequencing company.
Illumina says Complete Genomics rejects buyout offer
- Genetic sequencing company Illumina Inc said smaller peer Complete Genomics Inc rejected its takeover bid of about $114 million.
Competitors
| Price | Change | |
|---|---|---|
| Affymetrix, Inc. (AFFX.OQ) | $3.69 | -0.02 |
| Agilent Technologies Inc. (A.N) | $45.56 | +0.57 |
| Helicos BioSciences Corp. (HLCSQ.PK) | $0.00 | -0.00 |
| General Electric Company (GE.N) | $23.46 | +0.19 |
| Life Technologies Corp. (LIFE.OQ) | $73.54 | +0.05 |
| Luminex Corporation (LMNX.OQ) | $18.41 | +0.30 |
| Roche Holding Ltd. (ROG.VX) | CHF247.00 | +1.00 |
| Pacific Biosciences of California (PACB.OQ) | $2.42 | -0.05 |
| Qiagen NV (QGEN.DE) | €14.56 | +0.05 |
| Complete Genomics, Inc. (GNOM.OQ) | -- | -- |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
